The consensus, or mean, target price of the Wall Street analysts covering NuVasive is $54.9, according to a Markets Daily report.
Here are four observations:
1. Ten research firms in total have issued ratings on NuVasive within the last year.
2. The highest estimate of the 10 analysts is that stock will reach $63 within the next year, while the lowest estimate sets the target price at $49.
3. Analysts have also placed the consensus earnings per share estimate for the current year at $1.13.
4. NuVasive recently reported financial results for the first quarter of 2015. NuVasive increased revenue 8.4 percent to $192.4 million in the first quarter. Also, full year 2015 GAAP earnings per share were projected at $1.12, compared to GAAP loss per share of $0.36 for 2014.